Clinical biopharmaceutical company: Kaleido Biosciences (KLDO)

Kaleido Biosciences, Inc. (NASDAQ: KLDO) was founded in January 2015, formerly known as VL32, Inc, In November of the same year, it was changed to its current name. Headquartered in Lexington, Massachusetts, the United States, it has 91 full-time employees. It is a medical care company in the clinical stage. It adopts a differentiated, chemically driven approach and focuses on using the potential of microbiome organs to treat diseases and improve human health.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

Kaleido Biosciences (KLDO) US Equities Encyclopedia

Kaleido Biosciences has established a human centered proprietary product platform for discovery and development. The company believes that food Research regulations, the company can quickly promote a wide range of new product candidates to non IND human clinical research. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

Kaleido Biosciences' candidate product is Microbiome Metabolic Therapies, or MMTs, which aims to regulate the metabolic output and distribution of microbiome by driving the function and distribution of existing microorganisms. To discover and develop MMT by industrial method, the company's original MMT is targeted glycans. Each targeted glycan is a collection of complex carbohydrates designed to regulate microbial metabolism to drive specific biological reactions. Kaleido Biosciences believes that its MMT may become a new therapy for various diseases and diseases. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

The human microbiome is usually a community of more than 30 trillion microorganisms, including bacteria, viruses, archaea and fungi, which exist in the human body and the body. Through thousands of years of coexistence, microorganisms and human beings have formed an intricate and mutually beneficial relationship. In view of the profound impact of microorganisms on human health, this highly complex microbial ecosystem is called "newly discovered organ". More and more studies have linked healthy microbiomes with overall human health, while ecological imbalance or imbalance in microbiomes is related to many human diseases, including those that may lead to serious morbidity and mortality. Some of these conditions include irritable bowel syndrome, Parkinson's disease, diabetes, metabolic syndrome, cancer, allergies, and ulcerative colitis. Microbial tissue and organ is still an undeveloped field in the field of medical care. Kaleido Biosciences believes that the company has unique advantages in transforming its commitment into human health solutions. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

Kaleido Biosciences has developed proprietary synthetic chemistry technology, enabling the company to create its MMT candidate products. The company believes that the main features of MMT candidate products include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

• Oral Administration - The company's MMT candidate is highly soluble and therefore can be administered orally.
• Limited systemic exposure - Limited systemic exposure was observed after oral administration of the company's MMT candidate products, minimizing off target biological effects.
• Selective metabolism - MMT candidates designed by the company are selectively metabolized by enzymes in the microbiome to stimulate reactions that ultimately reshape the function, composition and metabolites of the microbiome.
• Structure diversification - The MMT candidate of the company is not a single, structurally defined molecule, but a collection of molecules with multiple structures. This structural complexity usually distinguishes MMT from any individual dietary fiber, and the company believes that this is the main factor in the activity of its differentiated microbiome.
• Easy to expand - the company's MMT candidate products are produced using proprietary standard small molecular unit operations. These methods are scalable and cost-effective.
• Novel and proprietary - The company's MMT candidate products are protected by a strong intellectual property portfolio, including material composition and patented methods of use.

Kaleido Biosciences rapidly promoted its initial MMT candidate to non IND human clinical research according to the regulations supporting food research. This enables companies to gain valuable insights into the impact of their MMT candidate products on microbiome and human health, and then choose to allocate additional time and funds to develop drug candidates under IND or commercialize non drug products. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

Kaleido Biosciences (KLDO) US equity investment

Submitted by Kaleido Biosciences, Inc. (NASDAQ: KLDO) on January 11, 2019 IPO The prospectus is planned to be listed on NASDAQ on February 28/2019, with an offering price of US $20-22, 4.8 million shares issued and US $100 million raised, Goldman Sachs / J.P. Morgan / Morgan Stanley Underwriting. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kldo.html

• reference material: